Clinical trial · Interventional
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to probe the effect of SBRT as a treatment oligometastases of prostate cancer, regardless of basal treatment received, and I know the response, biochemical control, the progression-free survival as well as their impact on quality of life. Primary Objective: Local and symptomatic oligometastases Control of prostate cancer treated by SBRT. Secondary Objectives: Analyzing biochemical progression rates, progression-free survival, chemotherapy-free survival and overall survival. Analyze toxicities and quality of life of patients before and after treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oligometastatic Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic Body Radiation Therapy for Oligometastases | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SBRT
- description
- Stereotactic Body Radiation Therapy for Oligometastases (SBRT)
- interventionNames
- Radiation: Stereotactic Body Radiation Therapy for Oligometastases
Primary outcomes (1)
- measure
- Number of patients without disease progression of prostate cancer treated by SBRT
- timeFrame
- 5 years
- description
- Number of patients without disease progression of local and symptomatic oligometastases of prostate cancer treated by SBRT expressed as total number and percentage
Secondary outcomes (4)
- measure
- Overall Survival measured with Kaplan-Meier method
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed prostate cancer, who are currently being oligometastases / oligorrecurrencia after primary treatment for their disease. * Aged ≥ 18 years * Time to biochemical recurrence more than 1 year * PSA doubling time\> 3 months * Less than 5 bone metastases location (including spinal) or lymph node. * Without other metastases or recurrences by Choline PET or / and NMR Diffusion Length. * Signed and dated written informed consent form. Exclusion Criteria: * Patients currently treatment with abiraterone, enzalutamide, chemotherapy, immunotherapy or radioisotopes. * Patients unwilling or unable to comply with protocol requirements and scheduled visits.
References
Publications (1)
- DERIVEDConde-Moreno AJ, Lopez-Campos F, Hervas A, Morillo V, Mendez A, Puertas MDM, Valero-Albarran J, Gomez Iturriaga A, Rico M, Vazquez ML, Samper Ots PM, Perez-Romasanta LA, Pastor J, Ibanez C, Ferrer F, Zapatero A, Garcia-Blanco AS, Rodriguez A, Ferrer C. A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05). Pract Radiat Oncol. 2024 Sep-Oct;14(5):e344-e352. doi: 10.1016/j.prro.2024.04.022. Epub 2024 Jun 29. PMID 38944806